Schering, Sanofi execs face questions

Sanofi Pasteur

While they were reporting their earnings, Schering-Plough and Sanofi-Aventis executives both found themselves on a hot seat. Schering CEO Fred Hassan (photo) faced questions about how he managed the controversial Enhance study--even hearing hints that he should depart, as one analyst called the trial "the worst PR disaster I think I ever recall." That's a big change for Hassan, who's been lauded for bringing Schering out of the ditch since he took over in 2003.

Meanwhile, Sanofi's R&D chief, Paul Chew, plus some FDA staffers, are expected to be grilled by the House Energy and Commerce Committee today in a hearing about the antibiotic Ketek, which was linked with liver failure last February. The committee wants to know whether the FDA knew about a Ketek study that included falsified data.

- read the Hassan article
 

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.
Read more on

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.